Medicus Pharma Ltd. seeks shareholder approval at a special meeting on December 2, 2026 for three proposals: create an unlimited class of Class A preferred shares, authorize a common-share split, and allow adjournment if votes are insufficient.
If approved, the preferred shares could be issued in series, with the board setting voting, dividend, redemption, conversion and liquidation terms without another shareholder vote; the board says it has no present intent to issue them. The split would permit up to 50 post-split shares for each pre-split share if the board considers it necessary or desirable. The company effected a 50-to-1 consolidation on October 12, 2026; 1,891,826 common shares were outstanding on October 16, 2026.
At the maximum, the proposed split would substantially reverse that consolidation. Medicus says a split at or near the maximum could cause the bid price to fall below the $1.00 minimum for continued listing on The Nasdaq Capital Market; the board says it does not intend a ratio it expects would do so. The preferred-share and split resolutions each require at least two-thirds of votes cast; the adjournment proposal could postpone the meeting to no later than December 31, 2026.
Medicus Pharma Ltd. effected a 1-for-50 consolidation of its issued and outstanding common shares, effective October 12, 2026; the shares began trading on a post-consolidation basis on the Nasdaq Capital Market that day. Every 50 common shares were automatically consolidated into one new common share. Shareholders approved a consolidation of up to 1-for-50 on June 3, 2026, and the board approved the 1-for-50 ratio on September 24, 2026.
The consolidation did not modify common-share rights or preferences. Proportionate adjustments were made to exercise or conversion prices and share counts for outstanding equity awards, convertible securities, warrants and equity incentive plans. Fractional shares were rounded down, with cash paid in lieu.
Medicus Pharma Ltd. (MDCX) ownership amendment reports that Dr. Kenneth Melani may be deemed the beneficial owner of 3,248,741 common shares, or 3.6%. Velocity Fund Partners, LP directly owns 2,839,330 shares, or 3.2%, while Melani directly owns 409,411 shares. Melani disclaims beneficial ownership of the fund’s shares except to the extent of his direct ownership. The reported percentages are based on 89,762,721 common shares outstanding as of September 10, 2026.
Medicus Pharma Ltd. will effect a 50-to-1 consolidation of its common shares effective October 12, 2026. Trading on a consolidated basis is expected to begin at the commencement of trading on October 12, 2026.
Every 50 issued and outstanding common shares will be exchanged for one new common share. No fractional shares will be issued; holdings that would otherwise produce a fraction will be rounded down to the next whole share, with cash paid in lieu. Voting power and share rights will remain unchanged. Proportionate adjustments will be made to exercise prices and shares issuable upon exercise or conversion of outstanding equity awards, convertible securities and warrants, and to shares under equity incentive plans. The company name and MDCX ticker will remain unchanged.
Medicus Pharma Ltd. (MDCX) discloses that its Chief Executive Officer and Executive Chairman, Dr. Raza Bokhari, together with RBx Capital, LP, has beneficial ownership of 4,859,349 common shares of Medicus Pharma, representing 5.3% of the company’s common shares on a beneficial ownership basis.
Dr. Bokhari’s position includes 2,941,176 common shares held directly, 1,125,000 common shares underlying stock options that are currently exercisable or will become exercisable within 60 days, and 793,173 common shares held by RBx Capital, LP, a Delaware limited partnership he controls. RBx Capital’s holdings alone represent 0.9% of the class, based on 89,762,721 common shares outstanding as of September 10, 2026. The securities are held for investment and in connection with Dr. Bokhari’s roles at Medicus Pharma, and the reporting persons may increase or decrease their holdings over time depending on corporate, market, and regulatory considerations.
Medicus Pharma Ltd. (MDCX) reports that on September 11, 2026 it and YA II PN, Ltd. mutually agreed to terminate their Standby Equity Purchase Agreement (SEPA), which had allowed the company to issue and sell up to $15.0 million of common shares. At termination, there were no outstanding borrowings, advance notices, or common shares to be issued under the SEPA, and no fees are due by either party in connection with the termination. Yorkville Securities, LLC, an affiliate of YA II PN, Ltd., remains a sales agent under Medicus Pharma’s Equity Distribution Agreement dated December 29, 2025, as amended.
Medicus Pharma Ltd. (MDCX) reported that on September 4, 2026 it granted an aggregate of 8,529,412 restricted common shares to certain officers and employees who elected to forgo cash bonuses. These shares represent the value of approximately $1.45 million of cash bonuses, converted at $0.1705 per share, the Nasdaq Capital Market closing price on September 3, 2026.
No additional cash consideration changed hands in this issuance, which was made as a private offering exempt from registration under Section 4(a)(2) of the Securities Act of 1933.
Medicus Pharma Ltd. (MDCX) reported that Chief Operating Officer Smith Andrew Alasdair received equity awards on September 4, 2026. He was granted stock options for 125,000 common shares at an exercise price of $0.1705 per share, scheduled to vest quarterly in four equal installments over one year and expiring on September 4, 2031. He also acquired 735,294 common shares at $0.1705 per share, bringing his direct common share holdings to 735,458 shares and his option holdings to 125,000 shares; no Rule 10b5-1 trading plan is reported.
Medicus Pharma Ltd. (MDCX) reported that Chief Medical Officer Mehmud Faisal received an equity award on September 4, 2026. He was granted a stock option to acquire 250,000 Common Shares at an exercise price of $0.1705 per share, expiring September 4, 2031, vesting quarterly in four equal installments over one year. He also received a direct grant of 1,470,588 Common Shares at $0.1705 per share, bringing his direct common share holdings to 1,470,588 shares. No Rule 10b5-1 trading plan is reported for these awards.
Medicus Pharma Ltd. (MDCX) reported that Chief Scientific Officer Brennan Edward J. received equity awards on September 4, 2026. He was granted 100,000 stock options with an exercise price of $0.1705 per common share, expiring on September 4, 2031, and 588,235 common shares at $0.1705 per share. The option is scheduled to vest quarterly in four equal installments over one year, and his directly held common share position increased to 674,735 shares. No Rule 10b5-1 trading plan is reported for these awards.